Future clinical trials will be conducted to investigate whether the combination of chloroquine and venetoclax can prevent disease recurrence.
Although new drugs have been developed to induce cancer cell death in individuals with acute myeloid leukemia, the leukemic cells often develop resistance and evade the drugs’ effects within a year.
Recently, research conducted using both human tissue samples and mouse models has uncovered that the resistance of leukemia cells to the widely used drug venetoclax is due to an abrupt surge in the breakdown and turnover of mitochondria. These structures within the cell play a crucial role in generating energy and also signal the cell to undergo programmed cell death under certain adverse conditions.
Led by scientists at NYU Langone Health and its Perlmutter Cancer Center, the study showed that mitophagy helps leukemia cells to evade the killing effects of venetoclax, a drug in a class of medications known as BH3 mimetics.
In a study recently published in the journal Cancer Discovery, researchers found that the levels of several genes associated with mitophagy were increased in 20 leukemia patient samples compared with normal controls. The level of these genes was even higher in samples from leukemia patients with drug resistance than in those leukemic patients who were not. Particularly notable was the increased expression of the gene for Mitofusin-2 (MFN2), which codes for a key protein in the outer mitochondrial membrane.
Further experiments using mice into which bone marrow from acute myeloid leukemia patients was transplanted showed that the drug chloroquine, a known mitophagy inhibitor, restored the ability of venetoclax to kill the cancer cells.
“Overcoming resistance to BH3 mimetic drugs like venetoclax is of unique clinical significance because these medications are often used for treating people with acute myeloid leukemia,” said study co-lead investigator Christina Glytsou, Ph.D., a former postdoctoral researcher at NYU Grossman School of Medicine and now an assistant professor at Rutgers University.
“Acute myeloid leukemia is notoriously difficult to treat, with fewer than a third of those affected living longer than five years after their diagnosis, so it is important to maximize the impact of existing therapies,” said study co-lead investigator Xufeng Chen, Ph.D., an instructor in the Department of Pathology at NYU Grossman.
“Our preclinical findings suggest that combining BH3 mimetics like venetoclax with either MFN2 or general mitophagy inhibitors could possibly serve as a future therapy for acute myeloid leukemia, as current drug treatments are stalled due to drug resistance,” said study senior investigator Iannis Aifantis, Ph.D.
Aifantis, the Hermann M. Biggs Professor and chair of the Department of Pathology at NYU Grossman and Perlmutter, says the research team plans to design a clinical trial to test whether chloroquine, when used in combination with venetoclax, prevents drug resistance in people with acute myeloid leukemia.
Speaking about other study results, the researchers say they not only found that MFN2 was overly active in people with drug-resistant disease, but also that cancer cells exposed to similar cell-death-inducing compounds demonstrated a doubling in mitophagy rates.
Additional testing in cancer cells engineered to lack MFN2 showed increased sensitivity to drugs similar to venetoclax compared with cells that had functional MFN2. The new study and previous research by the team showing misshapen mitochondria in drug-resistant leukemic cells confirmed that increased mitophagy was the source of the problem.
Acute myeloid leukemia, the most common form of adult leukemia, originates in the bone marrow cells and involves the rapid buildup of abnormal blood cells. The blood cancer results in the deaths of more than 11,500 Americans annually. Current treatments include chemotherapy and a limited number of targeted drug therapies. Bone marrow transplantation has also been used when other options fail.
Reference: “Mitophagy promotes resistance to BH3 mimetics in acute myeloid leukemia” by Christina Glytsou, Xufeng Chen, Emmanouil Zacharioudakis, Wafa Al-Santli, Hua Zhou, Bettina Nadorp, Soobeom Lee, Audrey Lasry, Zhengxi Sun, Dimitrios Papaioannou, Michael Cammer, Kun Wang, Tomasz Zal, Malgorzata Anna. Zal, Bing Z. Carter, Jo Ishizawa, Raoul Tibes, Aristotelis Tsirigos, Michael Andreeff, Evripidis Gavathiotis and Iannis Aifantis, 24 April 2023, Cancer Discovery.
DOI: 10.1158/2159-8290.CD-22-0601
The study was funded by the National Science Foundation. Additional funding support was provided by the Leukemia & Lymphoma Society and by AstraZeneca, which provided several of the BH3 mimetic drugs used in these experiments.
Aifantis has received additional research funding from AstraZeneca. This arrangement is being managed in accordance with the policies and practices of NYU Langone Health.
News
Scientists Sound Alarm: “Safe” Antibiotic Has Led to an Almost Untreatable Superbug
A recent study reveals that an antibiotic used for liver disease patients may increase their risk of contracting a dangerous superbug. An international team of researchers has discovered that rifaximin, a commonly prescribed antibiotic [...]
Scientists Discover Natural Compound That Stops Cancer Progression
A discovery led by OHSU was made possible by years of study conducted by University of Portland undergraduates. Scientists have discovered a natural compound that can halt a key process involved in the progression [...]
Scientists Just Discovered an RNA That Repairs DNA Damage – And It’s a Game-Changer
Our DNA is constantly under threat — from cell division errors to external factors like sunlight and smoking. Fortunately, cells have intricate repair mechanisms to counteract this damage. Scientists have uncovered a surprising role played by [...]
What Scientists Just Discovered About COVID-19’s Hidden Death Toll
COVID-19 didn’t just claim lives directly—it reshaped mortality patterns worldwide. A major international study found that life expectancy plummeted across most of the 24 analyzed countries, with additional deaths from cardiovascular disease, substance abuse, and mental [...]
Self-Propelled Nanoparticles Improve Immunotherapy for Non-Invasive Bladder Cancer
A study led by Pohang University of Science and Technology (POSTECH) and the Institute for Bioengineering of Catalonia (IBEC) in South Korea details the creation of urea-powered nanomotors that enhance immunotherapy for bladder cancer. The nanomotors [...]
Scientists Develop New System That Produces Drinking Water From Thin Air
UT Austin researchers have developed a biodegradable, biomass-based hydrogel that efficiently extracts drinkable water from the air, offering a scalable, sustainable solution for water access in off-grid communities, emergency relief, and agriculture. Discarded food [...]
AI Unveils Hidden Nanoparticles – A Breakthrough in Early Disease Detection
Deep Nanometry (DNM) is an innovative technique combining high-speed optical detection with AI-driven noise reduction, allowing researchers to find rare nanoparticles like extracellular vesicles (EVs). Since EVs play a role in disease detection, DNM [...]
Inhalable nanoparticles could help treat chronic lung disease
Nanoparticles designed to release antibiotics deep inside the lungs reduced inflammation and improved lung function in mice with symptoms of chronic obstructive pulmonary disease By Grace Wade Delivering medication to the lungs with inhalable nanoparticles [...]
New MRI Study Uncovers Hidden Lung Abnormalities in Children With Long COVID
Long COVID is more than just lingering symptoms—it may have a hidden biological basis that standard medical tests fail to detect. A groundbreaking study using advanced MRI technology has uncovered significant lung abnormalities in [...]
AI Struggles with Abstract Thought: Study Reveals GPT-4’s Limits
While GPT-4 performs well in structured reasoning tasks, a new study shows that its ability to adapt to variations is weak—suggesting AI still lacks true abstract understanding and flexibility in decision-making. Artificial Intelligence (AI), [...]
Turning Off Nerve Signals: Scientists Develop Promising New Pancreatic Cancer Treatment
Pancreatic cancer reprograms nerve cells to fuel its growth, but blocking these connections can shrink tumors and boost treatment effectiveness. Pancreatic cancer is closely linked to the nervous system, according to researchers from the [...]
New human antibody shows promise for Ebola virus treatment
New research led by scientists at La Jolla Institute for Immunology (LJI) reveals the workings of a human antibody called mAb 3A6, which may prove to be an important component for Ebola virus therapeutics. [...]
Early Alzheimer’s Detection Test – Years Before Symptoms Appear
A new biomarker test can detect early-stage tau protein clumping up to a decade before it appears on brain scans, improving early Alzheimer’s diagnosis. Unlike amyloid-beta, tau neurofibrillary tangles are directly linked to cognitive decline. Years [...]
New mpox variant can spread rapidly across borders
International researchers, including from DTU National Food Institute, warn that the ongoing mpox outbreak in the Democratic Republic of the Congo (DRC) has the potential to spread across borders more rapidly. The mpox virus [...]
How far would you trust AI to make important decisions?
From tailored Netflix recommendations to personalized Facebook feeds, artificial intelligence (AI) adeptly serves content that matches our preferences and past behaviors. But while a restaurant tip or two is handy, how comfortable would you [...]
Can AI Really Think? Research Reveals Gaps in Logical Execution
While AI models can break down problems into structured steps, new research reveals they still fail at basic arithmetic and fact-checking—raising questions about their true reasoning abilities. Large Language Models (LLMs) have become indispensable [...]
